Key statistics
On Friday, Corcept Therapeutics Inc (0I3Q:LSE) closed at 41.52, -5.03% below its 52-week high of 43.72, set on Sep 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 41.52 |
Low | 41.52 |
Bid | -- |
Offer | -- |
Previous close | 41.52 |
Average volume | 1.45k |
---|---|
Shares outstanding | 104.49m |
Free float | 92.42m |
P/E (TTM) | 37.16 |
Market cap | 4.41bn USD |
EPS (TTM) | 1.14 USD |
Data delayed at least 20 minutes, as of Sep 20 2024 18:07 BST.
More ▼
Announcements
- Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
- Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
- Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
- Corcept Completes Enrollment in Phase 4 CATALYST Trial
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
- Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
More ▼